Kenji Hattori

Protection against Oxidative Stress-induced Cell Death by Intracellular Platelet-activating Factor-Acetylhydrolase II

Platelet-activating factor-acetylhydrolase (PAF-AH), which removes the acetyl group at the sn-2 position of PAF, is distributed widely in tissues and plasma. Tissue cytosol contains at least two types of PAF-AH, isoforms Ib and II. Isoform Ib is a tertiary G-protein complex-like heterotrimeric enzyme that is involved in brain development such as formation of the brain cortex. Isoform II (PAF-AH(II)), however, is a 40-kDa monomer and has an amino acid sequence that exhibits a 41% identity with that of plasma PAF-AH. Although PAF-AH(II) preferentialy hydrolyzes oxidized phospholipids as well as PAF in vitro, the function of this enzyme has not, as yet, been elucidated. Here, we report that PAF-AH(II) functions as an anti-oxidant phospholipase. PAF-AH(II) was found to be an N-myristoylated enzyme that has never been reported among lipases and phospholipases. In MDBK cells treated with oxidants, PAF-AH(II) translocated from cytosol to membranes within 20 min, whereas in cells treated with anti-oxidants, it translocated, conversely, from membranes to cytosol. Overexpression of PAF-AH(II) in Chinese hamster ovary-K1 cells suppressed oxidative stress-induced cell death, which occurs by apoptosis. These findings suggest that intracellular PAF-AH(II) translocates between cytosol and membranes in response to a redox state of the cell and protects the cell against oxidative stress most probably by hydrolyzing oxidized phospholipids.

Purification and Characterization of Platelet-activating Factor Acetylhydrolase II from Bovine Liver Cytosol

Platelet-activating factor (PAF) acetylhydrolase, which inactivates PAF by removing the acetyl group at the sn-−2 position, is distributed widely in plasma and tissues. In a previous study, we demonstrated that the PAF acetylhydrolase activity present in the soluble fraction of bovine brain cortex could be separated chromatographically into three peaks (tentatively designated isoforms Ia, Ib, and II) (Hattori, M., Arai, H., and Inoue, K.(1993) J. Biol. Chem. 268, 18748-18753). In this study, these three isoforms were also detected in kidney and liver cytosols, although their relative activity ratios in these tissues differed. In particular, isoform II was responsible for the majority of the bovine liver PAF acetylhydrolase activity. We purified isoform II from bovine liver cytosol to near homogeneity and demonstrated that it is a single 40-kDa polypeptide. This enzyme was inactivated by diisopropyl fluorophosphate and 5,5′-dithiobis(2-nitrobenzoic acid), suggesting that both serine and cysteine residues are required for the enzyme activity, and [H]diisopropyl fluorophosphate labeled only the 40-kDa polypeptide, confirming the enzymes identity. Isoform II showed a comparatively broader substrate specificity than isoform Ib. Isoform II hydrolyzed propionyl and butyroyl moieties at the sn-−2 position approximately half as effectively as it did PAF, whereas isoform Ib hardly hydrolyzed these substrates. Taken together with previous data, the current findings indicate that tissue cytosol contains at least two types of PAF acetylhydrolase with respect to polypeptide composition, substrate specificity, and tissue distribution and suggest that these two enzymes may share distinct physiological functions in tissues.

cDNA Cloning and Expression of Intracellular Platelet-activating Factor (PAF) Acetylhydrolase II ITS HOMOLOGY WITH PLASMA PAF ACETYLHYDROLASE

Platelet-activating factor (PAF) acetylhydrolase, which inactivates PAF by removing the acetyl group at the sn-2 position, is widely distributed in plasma and tissues. We previously demonstrated that tissue cytosol contains at least two types of PAF acetylhydrolase, isoforms Ib and II, and that isoform Ib is a heterotrimer comprising 45-, 30-, and 29-kDa subunits, whereas isoform II is a 40-kDa monomer. In this study, we isolated cDNA clones of bovine and human PAF acetylhydrolase isoform II. From the longest open reading frame of the cloned cDNAs, both bovine and human PAF acetylhydrolases II are predicted to contain 392 amino acid residues and to exhibit 88% identity with each other at the amino acid level. Both enzymes contain a Gly-X-Ser-X-Gly motif that is characteristic of lipases and serine esterases. Expression of isoform II cDNA in COS7 cells resulted in a marked increase in PAF acetylhydrolase activity. An immunoblot study using an established monoclonal antibody against the bovine enzyme revealed that the recombinant protein exists in the membranous fraction as well as the soluble fraction. Isoform II is expressed most abundantly in the liver and kidney in cattle, but low levels were also observed in other tissues. The amino acid sequence deduced from the cDNA of isoform II had no homology with any subunit of isoform Ib. Interestingly, however, the amino acid sequence of isoform II showed 41% identity with that of plasma PAF acetylhydrolase. Combined with previous data demonstrating that isoform II shows similar substrate specificity to plasma PAF acetylhydrolase, these results indicate that tissue type isoform II and the plasma enzyme may share a common physiologic function.

Establishment of bone marrow-derived endothelial cell lines from ts-SV40 T-antigen gene transgenic rats

Purpose. Postneonatal neovascularization is thought to result exclusively from the proliferation, migration, and remodeling of fully differentiated endothelial cells (ECs). Recently, it has been reported that bone marrow contains cells which can differentiate into ECs and contribute to neoangiogenesis in adult species. In this study, we tried to establish conditionally immortalized endothelial cell lines (TR-BME) derived from rat bone marrow.Methods. Mononuclear cells were isolated and differentiated into ECs at 37°C from the bone marrow of a transgenic rat harboring temperature-sensitive SV40 large T-antigen (ts T-Ag) gene. Then, the cells were transferred and incubated at 33°C, a permissive temperature for ts T-Ag. Expression of vascular endothelial growth factor (VEGF) receptor (VEGFR)-1, 2, Tie-1, 2 and von Willebrand factor (VWF) were assayed by reverse transcriptase-mediated polymerase chain reaction (RT-PCR).Results. We have established three cell lines incorporating 1,1′-dioctadecyl-3,3,3′,3-tetramethylindo-carbocyanine perchlorate (DiI-Ac-LDL) with a spindle shape. One of these, clone 2, strongly expressed VEGFR-2, and weakly expressed VEGFR-1 and VWF. In contrast, clone 8 showed strong expression of Tie-1, 2, and VWF, and weak expression of VEGFR-1,2. All markers were expressed strongly in clone 3.Conclusions. These data confirm that the above three TR-BME cells are novel ECs derived from bone marrow progenitors.

Cloning, Expression, and Characterization of Cytosolic Sulfotransferase Isozymes from Drosophila melanogaster

We have identified four cytosolic sulfotransferase (SULT) homologs in the genome database of Drosophila melanogaster, and have designated these genes dmST1-4. Each of these four isozymes was subsequently classified into a different and novel gene family, as determined by the low amino acid sequence homology (less than 40%) between them, and also toward their vertebrate homologs. The transcripts for these four SULT homologs were detectable at all developmental stages in D. melanogaster. In addition, three of these isozymes, the exception being dmST2, were successfully expressed and purified in Escherichia coli. These recombinant dmST1, 3, and 4 products showed high sulfating activity toward phenolic compounds such as vanillin and 4-nitrophenol, but showed no activity toward typical endogenous substrates such as tyramine and serotonin. DmST4 and dmST3 showed the lowest and highest K m values for 3′-phosphoadenosine-5′-phosphosulfate (PAPS) respectively. DmST4 also showed low but not negligible activity toward 20-hydroxyecdysone.

Cloning and expression of a novel sulfotransferase with unique substrate specificity from Bombyx mori.

We identified a cDNA encoding a putative cytosolic sulfotransferase (SULT) by searching the expressed sequence tag database of Bombyx mori, and subsequently obtained the full-length cDNA for this gene via rapid amplification of cDNA ends (RACE). We designated this gene bmST1, and showed by sequence analysis that it belongs to a novel SULT family. The tissue specificity of bmST1 mRNA expression was examined in fifth instar larvae by reverse transcriptase-polymerase chain reaction (RT-PCR), and transcripts were detectable in the silk gland, gut, fat body, and Malpighian tube. A recombinant form of bmST1 was then expressed using a gluthathione S-transferase (GST) gene fusion system, and it was purified from Escherichia coli. Purified bmST1 did not exhibit sulfating activity toward SULT substrates such as 4-nitrophenol, vanillin, hydroxysteroids, or monoamines. Surprisingly, however, recombinant bmST1 showed considerable activity toward 4-nitrocatechol and also gallate esters, although the catechins are not sulfated by this enzyme.

Synergistic effect of indomethacin and bleomycin on tumor growth produced by activating antitumor immunity

Cancer cells and macrophages produce large amounts of prostaglandin (PG) E2, which suppresses the cellular immune reaction in tumor-bearing animals (1). These findings suggest that an inhibitor of PG synthesis might be able to restore immune activity against tumors. It has been reported that indomethacin (IND) inhibits tumor growth when administered on its own and exhibits synergistic effects with several other biological response-modifiers in transplanted tumor models (2–4). In clinical studies, it has been reported that anti-inflammatory treatment may prolong the survival of undernourished patients with metastatic solid tumors (5). In addition, several studies have shown that antitumor drugs restore cellular immune responses. In one case, bleomycin (BLM) increased gamma interferon, tumor necrosis factor alpha, and nitric oxide production by macrophages (6). The above reports indicate that a marked synergistic effect on tumor growth is likely to be observed when IND and BLM are coadministered. To examine whether the tumorsuppressive effect of antitumor agents directly involves tumor growth, one well-known and useful approach is to use the severe combined immunodefficiency (SCID) mouse. The SCID mouse was discovered in 1983 and it has subsequently been shown to be defective in both T and B lymphocytes (7). In this report, in an attempt to make chemotherapy more effective, we have examined the effect of coadministration of BLM and IND on tumor growth in normal and SCID mice. MATERIALS AND METHODS

Xanthurenic acid is an endogenous substrate for the silkworm cytosolic sulfotransferase, bmST1.

Sulfotransferase enzymes are known to regulate physiologically active substances such as steroids and catecholamines in mammals. Although invertebrates also express sulfotransferases, their biological function is mostly unclear. In a previous study, we reported that 4-nitrocatechol and the gallete ester are substrates for the silkworm sulfotransferase bmST1. The K(m) of bmST1 for these substrates is high. However, endogenous substrates of bmST1 have not yet been determined. We therefore investigated endogenous bmST1 substrates and carried out a detailed expression profile analysis of bmST1. We found that xanthurenic acid, a tryptophan metabolite, is a possible endogenous substrate of bmST1. The K(m) of bmST1 for xanthurenic acid is low, in the μM range, which is lower than that for previously reported substrates. Additionally, xanthurenic acid is a tryptophan metabolite that characteristically shows toxicity in vivo. High dose administration of xanthurenic acid resulted in inhibition of cuticular biosynthesis. The expression of the bmST1 gene reached a maximal level in the Malpighian tubule at the 4th molting stage, when amino acid metabolism might be activated. Our results suggest that bmST1 plays a role in detoxification of xanthurenic acid in the silkworm.